← ANALYST RATINGS · TIPRANKS

TransMedics Group (TMDX): analyst forecast and price target

$70.78 −7.50% close 16.10.26 · market cap $2.7B · Healthcare · Medical - Devices IWM 0.09%
Price targets and ratings of

Analyst consensus

Moderate Buy

6 Buy3 Hold0 Sell

Ratings of 9 analysts in the last 3 months · top analysts only

12-month forecast

$100+41.3% upside

Based on 9 price targets given in the last 3 months, the average target is $100, the highest $122, the lowest $65.00. The average is +41.3% from the last price of $70.78.

$75.00$100$125$150Jan 26AprJulOctJan 27AprJulOctHigh$122Average$100Low$65.00
Highest target $122 Average target $100 Lowest target $65.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% Stifel Nicolaus $65.00 Hold −8.2% Reiterated 15.10.26on TipRanks 10:26 +1.0%next day −6.4%
William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% Canaccord Genuity $95.00 → $94.00−1.1% Buy +32.8% Reiterated 13.10.26on TipRanks 07:10 +1.2%next day −3.5%
Christopher Pasquale★★★★★★★★★★#1776 · hits 61% · avg +11.9% Nephron $120 Buy +69.5% Initiated 06.10.26on TipRanks Oct 7 05:20 −3.8%next day +1.2% · 5 days −1.3%
Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% Piper Sandler $100 Buy +41.3% Reiterated 05.10.26on TipRanks 07:56 +3.3%next day −3.8% · 5 days −6.2%
Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% TD Cowen $120 Buy +69.5% Reiterated 02.10.26on TipRanks 08:30 +0.7%next day +3.3% · 5 days −3.6%
Ryan Daniels★★★★★★★★★★#2878 · hits 48% · avg +5.8% William Blair — Buy — Reiterated 02.10.26on TipRanks 05:15 +0.7%next day +3.3% · 5 days −3.6%
Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% Needham $106 Buy +49.8% Assigned 22.09.26on TipRanks 05:45 +0.9%next day −0.5% · 5 days −3.4%
Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% Stifel Nicolaus $65.00 Hold −8.2% Reiterated 11.09.26on TipRanks 07:55 −4.2%next day +4.9% · 5 days +5.3%
Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% Piper Sandler $90.00 → $100+11.1% Buy +41.3% Reiterated 11.09.26on TipRanks 07:50 −4.2%next day +4.9% · 5 days +5.3%
William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% Canaccord Genuity $95.00 Buy +34.2% Reiterated 11.09.26on TipRanks 07:30 −4.2%next day +4.9% · 5 days +5.3%
Ryan Daniels★★★★★★★★★★#2878 · hits 48% · avg +5.8% William Blair — Buy — Reiterated 10.09.26on TipRanks 18:05 −4.2%next day +4.9% · 5 days +5.3%
Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% TD Cowen $120 Buy +69.5% Reiterated 08.09.26on TipRanks 01:35 −1.4%next day −1.7% · 5 days +0.9%
Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% Oppenheimer — Hold — Reiterated 24.08.26on TipRanks 10:13 −0.9%next day −0.3% · 5 days −9.8%
Allen Gong★★★★★★★★★★#2251 · hits 46% · avg +14.7% J.P. Morgan $73.00 Hold +3.1% Reiterated 06.08.26on TipRanks Aug 7 08:10 +5.0%next day +4.0% · 5 days +10.5%
Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% UBS $80.00 → $77.00−3.7% Hold +8.8% Assigned 05.08.26on TipRanks 09:10 −5.1%next day +5.0% · 5 days +13.4%
David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% Robert W. Baird $120 → $122+1.7% Buy +72.4% Reiterated 05.08.26on TipRanks 07:45 −5.1%next day +5.0% · 5 days +13.4%
Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% Evercore ISI $100 → $90.00−10.0% Buy +27.2% Reiterated 06.07.26on TipRanks 08:55 +2.6%next day +0.3% · 5 days +6.6%
Young Li★★★★★★★★★★#12189 · hits 16% · avg −26.1% Jefferies $145 Buy +104.9% Reiterated 28.10.25on TipRanks 12:20 −2.3%next day +3.5% · 5 days −4.1%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering TransMedics Group

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months William Plovanic★★★★★★★★★★Canaccord Genuity · #5377
Hits 43%218 of 504 Average return +1.3%
1 year William Plovanic★★★★★★★★★★Canaccord Genuity · #5377
Hits 43%218 of 504 Average return +1.3%
2 years William Plovanic★★★★★★★★★★Canaccord Genuity · #5377
Hits 43%218 of 504 Average return +1.3%

Most profitable

3 months William Plovanic★★★★★★★★★★Canaccord Genuity · #5377
Hits 43%218 of 504 Average return +1.3%
1 year William Plovanic★★★★★★★★★★Canaccord Genuity · #5377
Hits 43%218 of 504 Average return +1.3%
2 years William Plovanic★★★★★★★★★★Canaccord Genuity · #5377
Hits 43%218 of 504 Average return +1.3%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $94.22 at a price of $83.45 (+12.9%); now: $97.44 at $70.78 (+37.7%).

$70.00$80.00$90.00$100Sep 15Oct 1Oct 15Top analysts$100Average target$97.44Price$70.78

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

01020301215Oct 251184Nov211Dec143Jan 26246Feb2197Mar5186Apr1276May1368Jun1256Jul887Aug5135Sep4136Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy121312854
Buy76581313
Hold686756
Sell000000

Earnings and sales forecast

Next report: 04.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.30 (from $0.15 to $0.40). Last quarter: $0.44.

Sales

Next quarter’s sales estimate — $178M (from $170M to $188M). Last quarter: $190M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About TransMedics Group
  • CEO: Waleed H. Hassanein
  • Employees: 898
  • 200 Minuteman Road, Andover, MA, 01810, US
  • www.transmedics.com

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Data from the stock’s TipRanks forecast page, read 67 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗